TRUE - Treatment.com Appoints Dr. Essam Hamza as CEO and Director
(TheNewswire)
VANCOUVER, British Columbia – TheNewswire - October 18, 2023 – Treatment.com International Inc. (CSE:TRUE ) ( OTC:TREIF ) ( Frankfurt:939) (the“Company” or “Treatment”) is pleased to announce theappointment of Dr. Essam Hamza, MD to its Board of Directors and asChief Executive Officer, effective October 17, 2023. Dr.Hamza willalso join the Board on that date.
The appointment of Dr. Hamza follows a mandate to appoint a leaderwith a rare combination of extensive healthcare, technology andcapital markets experience capable of leading the Company through thenext phase of its growth. Dr.Hamza is a proven executer with a trackrecord of successfully founding, leading and growing transformationalhealthcare companies. Most recently, he was the founder, a Directorand CEO of CloudMD, a Vancouver based healthcare technology company.
Dr.Hamza is a seasoned and highly successful business visionary,steeped in medical and healthcare experience via his over 20 years asa medical doctor and a business builder as the founder of severalhealthcare companies including CloudMD Inc. From 2019 to 2022 atCloudMD, Dr. Hamza lead the company through tremendous growth, from ahandful of employees and approximately $4M in annual sales in Canada,to hundreds of employees and customers across North American and over$100M in annual sales.
“Dr.Hamza is a proven leader and has a track record of successdelivered through his extradonirary ability and understanding ofhealthcare, technology and entrepreneurship. I am excited for him totake the helm and lead the Company forward and create immense valuefor our shareholders,” said Dr. Kevin Peterson, Chairman.
Dr. Hamza stated “I’m very honoured and excited to join Treatmentat this incredible inflection point for the company. I have beenfollowing story over the years and feel like the product is now readyfor the next phase. The Company will now be focused oncommercialization of its proprietary and best in class A.I. medicaldiagnostic tool. Over the next few months we will be updating themarket on the progress of this commercialization and hope to announcesome early wins.”
The Board would like to thank Dr.Kevin Peterson for his efforts duringhis time as interim CEO. Dr. Peterson will continue with Treatment asChairman of the Board.
In connection with the management and executive appointments, theCompany has granted 1,400,000 stock options exercisable at $0.25 for afive-year term and 1,150,000 restricted share units, valid for athree-year term to certain executive officers and consultants to theCompany. The stock options and restricted share units are issuedpursuant to the Company’s share compensation plans and are subjectto vesting conditions.
FOR ADDITIONAL INFORMATION, CONTACT:
Dr. Essam Hamza, CEO
ehamza@treatment.com
(612) 788-8900
Cautionary Statements
This news release containsforward-looking statements that are based on Treatment.com’sexpectations, estimates and projections regarding its business and theeconomic environment in which it operates, including with respect tothe implementation of its shareholder communications initiative andthe timing thereof. Although Treatment.com believes the expectationsexpressed in such forward-looking statements are based on reasonableassumptions, such statements are not guarantees of future performanceand involve risks and uncertainties that are difficult to control orpredict. Therefore, actual outcomes and results may differ materiallyfrom those expressed in these forward-looking statements and readersshould not place undue reliance on such statements. Theseforward-looking statements speak only as of the date on which they aremade, and Treatment.com undertakes no obligation to update thempublicly to reflect new information or the occurrence of future eventsor circumstances, unless otherwise required to do so by law.
The Canadian Securities Exchangedoes not accept responsibility for the adequacy or accuracy of thisrelease.
Copyright (c) 2023 TheNewswire - All rights reserved.